# Gq/11 inhibitor payloads

Source: https://onco.cc/terms/gq11-inhibitor-payloads/  
OnCo record `gq11-inhibitor-payloads` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

These payloads block a cell signal that drives some melanomas. An antibody carries the inhibitor into cells bearing a melanoma-associated surface protein.

## Summary

DYP688 targets the surface protein PMEL and delivers the Gq/11 inhibitor SDZ475. A published phase 1 study in metastatic uveal melanoma and other GNAQ/GNA11-mutant melanomas reported human safety and preliminary activity. This is direct pathway inhibition rather than a conventional tubulin or DNA-damaging payload. The study was an early dose-escalation trial, so it does not establish a comparative survival benefit or approval.

## Fields

- Kind: Term
- Last checked: 2026-11-08
- Also known as: SDZ475; DYP688 payload; GNAQ GNA11 inhibitor conjugates

## Sources

- DYP688 phase 1 clinical study (2026): https://doi.org/10.1038/s41591-026-04518-z
- ClinicalTrials.gov: NCT05415072: https://clinicaltrials.gov/study/NCT05415072

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- terms: [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/)
- trials: [A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas](https://onco.cc/trials/nct05415072/)

---
JSON: https://onco.cc/api/v1/entities/gq11-inhibitor-payloads.json